You are viewing the site in preview mode
Skip to main content
|
No
|
Age (years)/Gender
|
Smoking history (pack-years)
|
Pathological types/Tumor stage
|
Treatment modality
|
Concurrent chemotherapy regimen
|
Induction chemotherapy regimen
|
Radiotherapy dose (Gy/fraction)
|
MLD (Gy)
|
Percentage of lung volume affected in subclinical ILD (%)
|
Time from treatment to grade 5 RP (months)
|
|---|
|
1
|
59/Male
|
20
|
Adenocarcinoma/postoperative recurrence
|
CCRT
|
Cisplatin + pemetrexed
|
Cisplatin + gemcitabine
|
60.0/30
|
12.12
|
< 25
|
3.3
|
|
2
|
77/Male
|
50
|
Squamous cell carcinoma/IIIB
|
RT
|
None
|
Carboplatin + gemcitabine
|
49.5/22
|
13.89
|
≥ 25
|
4.1
|
|
3
|
69/Male
|
50
|
Squamous cell carcinoma/IIIB
|
RT
|
None
|
Carboplatin + gemcitabine
|
38.0/19
|
12.19
|
≥ 25
|
1.2
|
|
4
|
71/Male
|
60
|
SCLC/IIIA
|
CCRT
|
Cisplatin + etoposide
|
Cisplatin + etoposide
|
60.0/30
|
12.65
|
< 25
|
6.8
|
|
5
|
62/Male
|
30
|
Squamous cell carcinoma/postoperative recurrence
|
CCRT
|
Carboplatin + paclitaxel
|
None
|
60.0/30
|
11.92
|
< 25
|
3.0
|
- RP, radiation pneumonitis; MLD, mean lung dose; ILD, interstitial lung disease; RT, radiation therapy; CCRT, concurrent chemoradiotherapy; SCLC, small-cell lung cancer
